Avoid common mistakes on your manuscript.
Past
In patients with locally advanced (LAPC) or borderline resectable (BRPC) pancreatic cancer, primary chemotherapy with or without radiotherapy is recommended for local downstaging to enable a potentially curable resection. FOLFIRINOX or gemcitabine-based chemotherapy are in common use. However, it is currently unclear what chemotherapy should be preferred for patients with LAPC and BRPC. Previous studies investigating this question are available, but often include a limited number of patients, combine LAPC with BRPC, or combine both chemotherapy regimen.1,2,3,4
Present
In this study, we report for the first time the outcomes separately for BRCP and LAPC, and by chemotherapy regimen including FOLFIRINOX or gemcitabine-based regimen with the largest patient number currently available from high-volume international centers (Eshmuminov et al. in press).5 Intriguingly, for resected patients, outcomes are similar between FOLFIRINOX or gemcitabine-based regimen for both BRPC and LAPC. Primary treatment with FOLFIRINOX compared with gemcitabine-based chemotherapy appears to provide a survival benefit for patients who are ultimately unresectable.
Future
FOLFIRINOX is preferred for patients with good performance status due to the survival benefit in patients who ultimately do not undergo resection. Gemcitabine-based regimen can be considered as a reasonable alternative to FOLFIRINOX, particularly in patients who have a less robust performance status. Nevertheless, resection offers the best chance for prolonged survival. Future prospective studies are necessary to optimize patient selection for each regimen as well as clarify the optimal duration of neoadjuvant treatment.
References
Perri G, Prakash L, Qiao W, et al. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg. 2020;155(9):832–9.
Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54(7):979–85.
Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932–42.
Kunzmann V, Siveke JT, Algul H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(2):128–38.
Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13353-2
Funding
Open access funding provided by University of Zurich.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Eshmuminov, D., Aminjonov, B., Palm, R.F. et al. ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal. Ann Surg Oncol 30, 4429–4430 (2023). https://doi.org/10.1245/s10434-023-13484-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-13484-6